Business Context and Reporting Period
This Form 8-K Current Report was filed by Ventrus Biosciences, Inc. (noted as Assembly Biosciences, Inc. in metadata) on January 30, 2013. The filing discloses the entry into material definitive agreements for a concurrent public offering of common stock and Series A Non-Voting Convertible Preferred Stock.
Key Financial Metrics and Transaction Details
- Expected Net Proceeds: Approximately $20 million from the combined offerings.
- Common Stock Offering: Sale of 5,800,000 shares at $2.50 per share to the public; underwriter purchase price is $2.35 per share.
- Series A Preferred Stock Offering: Sale of 220,000 shares at $25.00 per share to the public; underwriter purchase price is $23.50 per share.
- Over-Allotment Option: The underwriter (William Blair & Company, L.L.C.) holds a 30-day option to purchase up to 15% additional common shares.
- Closing Date: Expected on February 4, 2013.
Material Changes and Securities Structure
The filing details the issuance of new equity securities under an effective shelf registration statement (Form S-3). Key structural terms include:
- Conversion Rights: Each share of Series A Stock is convertible into 10 shares of common stock at the holder's option, subject to a beneficial ownership limitation of 9.98%.
- Liquidation Preference: Series A Stockholders receive $0.001 per share prior to common stockholders in a liquidation event.
- Dividends: Series A Stock is non-dividend bearing unless specifically declared by the board.
- Lock-Up Agreement: The company, its directors, and executive officers agreed not to sell or transfer common stock for 90 days following January 30, 2013, without underwriter consent.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, revenue projections, or management commentary regarding future operational performance. The primary risk disclosed relates to the dilution of existing shareholders due to the issuance of new common and convertible preferred stock. The transaction is contingent upon customary closing conditions and representations.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received on or after February 4, 2013.
- Confirm whether the underwriter exercised the 15% over-allotment option for common stock.
- Review the Certificate of Designation (Exhibit 4.14) for full details on Series A conversion mechanics and liquidation preferences.
- Monitor the company's cash burn rate and runway post-capital raise, as no operating financials are included in this filing.